Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition
Peter D. Zang, Neal Shiv Chawla, Regina Barragán-Carrillo, Alex Chehrazi‐Raffle, Abhishek Tripathi, Sumanta K. Pal, Tanya B. Dorff
Abstract
This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.
Topics & Concepts
MedicineProstate cancerOncologyInternal medicineCancerProstateImmunotherapyProstate Cancer Treatment and ResearchCancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics